Editor---Detection of airway opening pressure (AOP) above atmospheric pressure in patients with acute respiratory distress syndrome (ARDS) is a simple bedside measure with relevant physiological and clinical consequences.[@bib1] Airway opening pressure is the threshold level for start of alveolar inflation, and when it is higher than externally set PEEP, undetected AOP can lead to overestimation of driving pressure[@bib2] and to underestimation of the potential for lung recruitment.[@bib3] Several mechanisms contribute to the development of elevated AOP during ARDS, such as impaired surfactant.[@bib4] ^,^ [@bib5] The recent coronavirus disease 2019 (COVID-19) pandemic led to a dramatic surge in intubated patients with ARDS admitted to intensive care.[@bib6] The number of patients, the stress on healthcare workers, and the need for careful isolation limited the ability to perform extensive clinical and physiological testing in these patients.[@bib7] We present here unique physiological measures on the interdependence between AOP, pleural pressure (*P* ~pl~, estimated from oesophageal pressure), and intra-abdominal pressure (IAP) obtained by standard bedside monitoring in a patient affected by COVID-19 ARDS fully supported by extracorporeal membrane oxygenation (ECMO). The institutional ethics board of Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy approved this study. The data used or analysed are available from the corresponding author on reasonable request.

A 46-yr-old intubated patient was admitted to the ICU of the Ospedale Maggiore Policlinico with a diagnosis of severe ARDS from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection confirmed by reverse transcription--polymerase chain reaction. He had no co-morbidities except for mild depressive state and obesity (BMI=32). After 8 days, oxygenation had not improved despite multiple sessions of prone positioning and administration of nitric oxide, and decreased compliance hindered application of protective mechanical ventilation. Thus, veno-venous ECMO was started through a femoral--femoral approach. Tidal volume (*V* ~*t*~) was reduced to keep driving pressure \<14 cm H~2~O and ventilatory frequency (VF) to 10 bpm with PEEP of 15 cm H~2~O. Ten days later, respiratory conditions deteriorated further as a result of superinfection and alveolar bleeding, and a second ECMO system was added through a double-lumen jugular approach to produce peripheral oxygen saturation \>80%. On ECMO Day 18, the patient developed abdominal compartment syndrome and oliguria. Possible causes included intestinal obstruction from opioid-induced constipation, hypoperfusion, or SARS-CoV-2 infection itself.[@bib8] ^,^ [@bib9] The patient was ventilated on pressure-controlled mode, and as *V* ~*t*~ became minimal (0.7 ml kg^−1^ predicted body weight; [Supplementary Table S1](#appsec1){ref-type="sec"}) in association with development of abdominal hypertension, we performed comprehensive bedside physiological measures to monitor the clinical evolution and confirm physiological mechanisms. After 51 days, the patient died as a result of septic shock.

Using a standard ICU ventilator (Servo-u®; Getinge, Solna, Sweden), we were able to measure total PEEP, plateau pressure, and *V* ~*t*~ under clinical settings through end-inspiratory and end-expiratory occlusions. Keeping in mind that classic respiratory mechanics can be misinterpreted in the presence of AOP higher than PEEP, driving pressure was 12 cm H~2~O, plateau pressure was 31 cm H~2~O, and respiratory system compliance was 4.6 ml cm H~2~O^−1^ ([Supplementary Table S1](#appsec1){ref-type="sec"}). Measurement of calibrated oesophageal pressure (Esophageal Balloon Catheter Set; Cooper Surgical, Trumbull, CT, USA)[@bib10] using the haemodynamic monitor during occlusions allowed us to measure end-inspiratory and end-expiratory *P* ~pl~. *P* ~pl~ was extremely elevated, and the end-expiratory value was 30 cm H~2~O. The end-expiratory transpulmonary pressure was --11 cm H~2~O with a driving transpulmonary pressure of 11 cm H~2~O and an elastance-derived inspiratory transpulmonary pressure of 28 cm H~2~O ([Supplementary Table S1](#appsec1){ref-type="sec"}). A switch to volume-controlled mode with long inspiratory time (12 s), low VF (4 bpm), and *V* ~*t*~ \>300 ml allowed us to perform a low-flow pressure--volume (*P*--*V*) curve between 5 and 45 cm H~2~O, and to detect the AOP at the bedside ([Fig. 1](#fig1){ref-type="fig"} , left). We also manually collected the *P*--*V* values every 3 cm H~2~O and to form the classical *P*--*V* curve by commercial software ([Fig. 1](#fig1){ref-type="fig"}, right), which confirmed an AOP value of 30 cm H~2~O. The compliance of the respiratory system between 5 and 30 cm H~2~O was similar to the airway circuit (1.5--2 ml cm H~2~O^−1^). Recognition of an upper inflection point around 40 cm H~2~O may indicate over-distention of the ventilated regions, further suggesting that standard protective ventilation in this patient would have been impossible.Fig. 1Airway opening pressure (AOP). On the left, the airway pressure, flow, and volume *vs* time waveforms from the ventilator. The cursor indicates the AOP at 30 cm H~2~O. On the right, the *P*--*V* curve obtained by manual plotting of values obtained from the ventilator (see text for details). The dashed line shows the steep increase in the slope of the curve at the AOP (30 cm H~2~O).Fig. 1

Finally, 50 ml of normal saline was infused through the urinary catheter into the bladder. Then, the catheter was clamped and IAP was recorded at end expiration, showing a value of 30 cm H~2~O. Measures of IAP and AOP were repeated in the following days: as the abdominal condition improved, IAP gradually decreased, and after 1 week IAP was 15 cm H~2~O and AOP was 19 cm H~2~O.

In severe COVID-19 ARDS supported by ECMO, standard bedside physiological monitoring allowed us to show equalisation of extremely elevated IAP, *P* ~pl~, and AOP in the presence of abdominal compartment syndrome. The interdependence between IAP and AOP values was lost as the abdominal condition improved, with AOP remaining steadily high despite return to normal IAP values.

Airway closure in ARDS might result from elevated pleural pressure with reduced lung size causing compression of distal airways[@bib4] or depletion of surfactant with high surface tension causing airway collapse.[@bib5] Moreover, pleural pressure can be increased by external (e.g. abdominal pressure) or intrinsic (e.g. increased lung weight) forces.[@bib8] Perfect correspondence between IAP, *P* ~pl~, and AOP has not been reported previously and generates the hypothesis that the presence of extremely elevated IAP applied to a closed system (rigid abdominal and chest wall and collapsed non-ventilated lung) can become the only external force determining elevated pleural pressure and AOP. The persistence of elevated AOP even after the decrease of IAP may suggest that other mechanisms related to intrinsic compressive forces and surfactant dysfunction became predominant. Even though previous studies have not reported correspondence between AOP and pleural pressure,[@bib1] the almost complete lung collapse as a result of profound hypoventilation leading to a virtually closed intrathoracic system may explain the pressure equalisation that we observed. From a clinical point of view, the measurement of AOP may be useful to personalise PEEP or to perform further diagnostic investigations targeted at intestinal function.

The physiological measures in this COVID-19 ARDS patient supported with ECMO suggest a new mechanism for elevated AOP: extremely elevated IAP is transmitted to the pleural space and, in the presence of complete lung collapse, becomes the threshold value for airway opening.
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